JLE

Epileptic Disorders

MENU

Sialidoses Volume 18, supplement 2, September 2016

  • [Allegranza et al., 1989] Allegranza A., Tredici G., Marmiroli P. Pathological study in an adult. Clin Neuropathol. 1989;8:266-271.
  • [Bonten et al., 1996] Bonten E., van der Spoel A., Fornerod M., Grosveld G., d’Azzo A. A characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev. 1996;10:3156-3169.
  • [Bonten et al., 2000] Bonten E.J., Arts W.F., Beck M. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet. 2000;9:2715-2725.
  • [Canafoglia et al., 2011] Canafoglia L., Franceschetti S., Uziel G. Characterization of severe actionmyoclonus in sialidoses. Epilepsy Res. 2011;94:86-93.
  • [Canafoglia et al., 2014] Canafoglia L., Robbiano A., Pareyson D. Expanding sialidosis spectrum by genome-wide screening: mutations in adult-onset myoclonus. Neurology. 2014;82:2003-2006. NEU1
  • [Cantz et al., 1977] Cantz M., Gehler J., Spranger J., Mucolipidosis I. Increased sialic acid content and deficiency of an alpha-N-acetylneuraminidase in cultured fibroblasts. Biochem Biophys Res Commun. 1977;74:732-738.
  • [Engel et al., 1977] Engel J. Jr., Rapin I., Giblin D.R. Electrophysiological studies in two patients with cherry red spot-myoclonus syndrome. Epilepsia. 1977;18:73-77.
  • [Franceschetti et al., 1980] Franceschetti S., Uziel G., Di Donato S., Caimi L., Avanzini G. Cherry-red spot-myoclonus syndrome and alpha-neuraminidase deficiency: neurophysiological, pharmacological and biochemical study in an adult. J Neurol Neurosurg Psychiatry. 1980;43:934-940.
  • [Kivlin et al., 1985] Kivlin J.D., Sanborn G.E., Myers G.G. The cherry-red spot in Tay-Sachs and other storage diseases. Ann Neurol. 1985;17:356-360.
  • [Lowden and O’Brien, 1979] Lowden J.A., O’Brien J.S. Sialidosis: a review of human neuraminidase deficiency. Am J Hum Genet. 1979;31:1-18.
  • [Lukong et al., 2001] Lukong K.E., Landry K., Elsliger M.A. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex. J Biol Chem. 2001;276:17286-17290.
  • [Minassian et al., 2016] Minassian B.A., Striano P., Avanzini G. Progressive Myoclonus Epilepsies: State-of-the-Art. Epileptic Disord. 2016;18:S1-S158. Suppl. 2
  • [Nirenberg and Frucht, 2005] Nirenberg M.J., Frucht S.J. Myoclonus. Curr Treat Options Oncol. 2005;7:221-230.
  • [Palmeri et al., 2000] Palmeri S., Villanova M., Malandrini A. Type I sialidoses: a clinical, biochemical and neuroradiological study. Eur Neurol. 2000;43:88-94.
  • [Panzica et al., 2003] Panzica F., Canafoglia L., Franceschetti S. Movement-activated myoclonus in genetically defined progressive myoclonic epilepsies: EEG-EMG relationship estimated using autoregressive models. Clin Neuro Physiol. 2003;114:1041-1052.
  • [Pattison et al., 2004] Pattison S., Pankarican M., Rupar C.A., Graham F.L., Igdoura S.A. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression. Hum Mutat. 2004;23:32-39.
  • [Pshezhetsky et al., 1997] Pshezhetsky A.V., Richard C., Michaud L. Cloning, expression and chromosomal mapping of human lysosomal sialidase and characterization of mutations in sialidosis. Nat Genet. 1997;15:316-320.
  • [Rapin et al., 1978] Rapin I., Goldfischer S., Katzman R., Engel J., O’Brien J.S. The cherry-red spot-myoclonus syndrome. Ann Neurol. 1978;3:234-242.
  • [Schene et al., 2015] Schene I.F., Ayuso V.K., de Sain-van der Velden M. Pitfalls in diagnosing neuraminidase deficiency: psychosomatics and normal sialic acid excretion. JIMD Rep. 2015;25:9-13.
  • [Spranger et al., 1978] Spranger J., Cantz M., Mucolipidosis I. The cherry red-spot-myoclonus syndrome and neuraminidase deficiency. Birth Defects Orig Artic Ser. 1978;14:105-112.
  • [Thomas et al., 1979] Thomas P.K., Abrams J.D., Swallow D., Stewart G. Sialidosis type1, cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobilities of some enzymes known to be glycoproteins. 1. Clinical findings. J Neurol Neurosurg Psychiatry. 1979;42:873-880.
  • [Tobimatsu et al., 1985] Tobimatsu S., Fukui R., Shibasaki H., Kato M., Kuroiwa Y. Electrophysiological studies of myoclonus in sialidosis type 2. Electroencephalogr Clin Neurophysiol. 1985;60:16-22.
  • [Wang et al., 2005] Wang D., Bonten E.J., Yogalingam G., Mann L., d’Azzo A. Short-term, high dose enzyme replacement therapy in sialidosis mice. Mol Genet Metab. 2005;85:181-189.
  • [Yogalingam et al., 2008] Yogalingam G., Bonten E.J., van de Vlekkert D. Neuraminidase 1 is a negative regulator of lysosomal exocytosis. Dev Cell. 2008;15:74-86.